BURLINGTON — LabCorp has launched a non-invasive test for patients with non-small cell lung cancer (NSCLC), the company announced on Wednesday.

Called Resolution ctDx Lung, the liquid biopsy test is done using a blood sample to detect mutations in genes associated with NSCLC, allowing for more individualized treatment options. The test is covered by Medicare.

“Oncology is an area of intense focus for LabCorp, across our entire organization. The Resolution ctDx Lung test is the latest example of our commitment to provide patients and clinicians with cutting-edge testing and personalized information to make the best possible treatment decisions. This innovative test is an outstanding addition to our industry leading offerings for oncology patients,” Dr. Brian Caveney, president of LabCorp Diagnostics, said in a statement.

The test was developed by Resolution Bioscience. The partnership gives LabCorp access to Resolution Bioscience’s patented cell-free DNA (cfDNA) analysis platform, which is essential to the test’s capabilities.

“This commercial partnership with LabCorp is an important step in our quest to enable broad access to our lung cancer test and improve clinical outcomes for more people battling NSCLC,” Resolution Bioscience CEO Mark Li said.

According to Li, the test “consistently detects more driver and resistance mutations than competing platforms.”

The Resolution ctDx Lung test is currently being used in a study to select the appropriate plasma-directed therapy for NSCLC patients and has shown a 95 percent positive clinical response, showing the test’s ability to choose the appropriate therapies, according to the release.

Shares of Laboratory Corporation of America Holdings (LH) were last trading 1.80 percent lower near $181.58 on Wednesday.

The release is available here.

This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism